Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.39 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5928905 | 0.83 | TLR8 (0.47) | TLR8TSHR | |
| SCHEMBL2560827 | 0.79 | KDM4E (0.38) | TSHRLMNAMAPT | |
| SCHEMBL5928902 | 0.78 | TLR8 (0.43) | TLR8TSHRLMNAMAPT | |
| SCHEMBL5929077 | 0.77 | TLR8 (0.42) | TLR8AGTR1AGTR2 | |
| SCHEMBL1912824 | 0.73 | PTGER4 (0.35) | TSHR | |
| SCHEMBL18152746 | 0.73 | TLR8 (0.48) | TLR8TSHRCNR2TDP1L3MBTL1 | |
| SCHEMBL1422956 | 0.68 | HPGD (0.45) | TSHRMAPTTDP1 | |
| SCHEMBL28516123 | 0.68 | AGTR1 (0.47) | AGTR1AGTR2GP6 | |
| SCHEMBL5929307 | 0.68 | TLR8 (0.38) | TLR8TSHR | |
| SCHEMBL1912807 | 0.68 | TSHR (0.55) | AGTR2TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | NEUROGEN CORPORATION (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2005007087-A2 | SUBSTITUTED (HETEROCYCLOALKYL)METHYL AZOLE DERIVATIVES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | C5AR1, C5AR2, C3AR1 | TLR8 202/4885AGTR1 46/4885AGTR2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.